EMA Authorised: Kineret (anakinra) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

EMA authorised Kineret (anakinra) by Swedish Orphan Biovitrum AB (publ) with an expanded indication to include COVID-19 infection in addition to rheumatoid arth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• KINERET (ANAKINRA)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;COVID-19 virus infection. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 04/09/2025